15 July 2013

Immunocore signs research and licensing agreement with GlaxoSmithKline

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs called ImmTACs to treat cancer and viral disease, today announced it has entered into a partnership with GlaxoSmithKline (GSK) for multiple novel targets not addressable using antibody-based technologies. This is Immunocore’s second major partnership this year.

Please click on the link below to download the full Press Release:-

Immunocore signs research and licensing agreement with GlaxoSmithKline – July 2013